Scientists at Oregon State University have patented a novel magnetic resonance imaging (MRI) contrast agent design that demonstrates potential to outperform current clinical standards while offering reduced patient toxicity and enhanced environmental sustainability.
The innovative material, named BVR-19 (derived from OSU’s beaver mascot), utilizes a manganese-based metal-organic framework (MOF) structure—the same technology recognized with this year’s Nobel Prize in Chemistry—positioning it as a promising alternative to conventional gadolinium-based contrast agents.
Technology Innovation and Design Advantages
BVR-19 represents a significant advancement in contrast agent engineering through its unique MOF architecture, which combines positively charged manganese ions with organic linker molecules to create nanoscale pores that can be precisely tailored for specific imaging applications.
Unlike gadolinium—a rare earth element with growing toxicity concerns and supply chain vulnerabilities—manganese is abundantly available in Earth’s crust and essential to human health in trace amounts, functioning in antioxidant protection, bone formation, and metabolic processes.
Market Context and Clinical Need
The development addresses critical challenges in the global MRI contrast agent industry, valued at over 1.5billionand projected to expand by 750 million within five years.
Current gadolinium-based agents, used for nearly four decades, present well-documented limitations including patient retention risks (with gadolinium persisting in tissues for months or years even in patients with normal kidney function) and environmental concerns as these agents pass through wastewater systems virtually unchanged due to their resistance to degradation in treatment plants.
Performance and Safety Advantages
Experimental results demonstrate that BVR-19 achieves brighter, clearer images at lower doses compared to commercially available agents. Its synthesis occurs in water at room temperature without requiring toxic solvents or harsh conditions, aligning with green chemistry principles.
The incorporation of L-cystine, a naturally occurring biocompatible amino acid, further enhances its safety profile. “BVR-19 represents a paradigm shift in MRI contrast agent design,” said lead researcher Kyriakos Stylianou, director of OSU’s Materials Discovery Lab.
Research Collaboration and Multidisciplinary Approach
The project exemplifies cross-institutional collaboration, involving researchers from OSU’s College of Science and College of Agricultural Sciences, along with partners at Oregon Health & Science University.
First authors Jacob Lessard (doctoral student) and Dylan Pyle (undergraduate) led the study published in the Journal of Materials Chemistry B, with contributions from multiple team members specializing in materials science, toxicology, and medical applications.
Future Implications and Translation Potential
“This research underscores OSU’s leadership in designing functional MOFs for medical and environmental applications,” Stylianou noted. “It demonstrates how green chemistry and materials design can converge to create safer technologies that connect fundamental discoveries with improved human health outcomes.”
The technology offers a sustainable pathway for the contrast agent industry while addressing growing regulatory concerns about gadolinium retention, potentially benefiting millions of patients undergoing MRI procedures annually while reducing environmental impact.
Related topics:
